Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
July 18 2022 - 8:25AM
Business Wire
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a
commercial-stage, cancer prevention medical diagnostics company,
and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,
PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman
and CEO, has been invited to present at the CG 42nd Annual Growth
Conference taking place at the InterContinental Boston from August
8 – 11. Dr. Aklog will deliver a company presentation in the
Hutchinson Room on Thursday, August 11, from 12:30 pm – 12:55 pm
ET. In addition, Lucid will host 1x1 investor meetings during the
conference. Register to watch Dr. Aklog’s presentation at
https://wsw.com/webcast/canaccord76/lucd/2445912. Please contact
your Canaccord representative to schedule a 1x1 meeting.
Dr. Lishan Aklog will also present at the 7th Annual Needham Med
Tech & Diagnostics 1x1 Conference taking place from August 15 –
16. Dr. Aklog will participate in 1x1 investor meetings on Tuesday,
August 16, from 8:00 am - 3:00 pm ET. Please contact your Needham
representative to schedule a 1x1 meeting.
About Lucid Diagnostics
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage,
cancer prevention medical diagnostics company, and subsidiary of
PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of
patients with gastroesophageal disease (GERD), also known as
chronic heartburn, who are at risk of developing esophageal
precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test,
performed on samples collected in a brief, noninvasive office
procedure with its EsoCheck® Esophageal Cell Collection Device, is
the first and only commercially available diagnostic test capable
of serving as a widespread screening tool to prevent cancer and
cancer deaths through early detection of esophageal precancer in
at-risk GERD patients. EsoGuard is commercialized in the U.S. as a
Laboratory Developed Test (LDT). EsoCheck is commercialized in the
U.S. as a 510(k)-cleared esophageal cell collection device.
EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device
designation and is the subject of multiple ongoing clinical trials.
Lucid is building nationwide direct sales and marketing team
targeting primary care physicians, specialists and institutions, as
well as a network of Lucid Test Centers where at-risk GERD patients
can undergo the EsoCheck procedure for EsoGuard testing. For more
information, please visit www.luciddx.com, follow Lucid on Twitter,
and connect with Lucid on LinkedIn. For detailed information on
EsoGuard, please visit www.EsoGuard.com and follow us on Twitter,
Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of Lucid’s management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of Lucid’s common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance Lucid’s products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from Lucid’s clinical and
preclinical studies; whether and when Lucid’s products are cleared
by regulatory authorities; market acceptance of Lucid’s products
once cleared and commercialized; Lucid’s ability to raise
additional funding as needed; and other competitive developments.
In addition, Lucid has been monitoring the COVID-19 pandemic and
the pandemic’s impact on Lucid’s businesses. Lucid expects the
significance of the COVID-19 pandemic, including the extent of its
effect on its financial and operational results, to be dictated by,
among other things, the success of efforts to contain the pandemic
and the impact of such efforts on Lucid’s businesses. These factors
are difficult or impossible to predict accurately and many of them
are beyond Lucid’s control. In addition, new risks and
uncertainties may arise from time to time and are difficult to
predict. For a further list and description of these and other
important risks and uncertainties that may affect Lucid’s future
operations, see Part I, Item IA, “Risk Factors,” in Lucid’s most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, as the same may be updated in Part II, Item
1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by
Lucid, as applicable, after its Registration Statement No.
333-259721 filed with the Securities and Exchange Commission. Lucid
disclaim any intention or obligation to publicly update or revise
any forward-looking statement to reflect any change in its
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220718005081/en/
Investors Adrian K. Miller Lucid Diagnostics
AKM@luciddx.com
Media Shani Lewis LaVoieHealthScience (609) 516-5761
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From May 2024 to Jun 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
From Jun 2023 to Jun 2024